Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

125 та иш

Иш: CAR‐NK Cell Biology and Engineering for Solid Tumors, With a Focus on Lung Cancer

  1. Disorders of cancer metabolism: The therapeutic potential of cannabinoids

    Dingya Sun, Xin Li, Shengdan Nie +2

    Шарҳ мақола20229 иқтибос
    ABI

  2. Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer

    Yunbo Nie, Dan Li, Ying Peng +5

    Мақола20209 иқтибос
    ABI

  3. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

    Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5

    Шарҳ мақола20257 иқтибос
    ABI

  4. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies

    Ding-Ya Sun, Yijie Hu, Xin Li +3

    Шарҳ мақола20247 иқтибос
    ABI

  5. Anticancer Activity and Mechanism of Xanthohumol: A Prenylated Flavonoid From Hops (Humulus lupulus L.)

    Chuanhao Jiang, Taoli Sun, Daxiong Xiang +2

    Шарҳ мақола20186 иқтибос
    ABI

  6. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Enli Liu, David Marín, Pinaki P. Banerjee +24

    Мақола20206 иқтибос
    ABI

  7. A <scp>TGF</scp>‐β signaling‐related <scp>lncRNA</scp> signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

    Weiwei Duan, Liting Yang, Jian Liu +13

    Мақола20236 иқтибос
    ABI

  8. Platinum–Iron Nanoparticles for Oxygen-Enhanced Sonodynamic Tumor Cell Suppression

    Qianya Dong, Zhenqi Jiang

    Мақола20245 иқтибос
    ABI

  9. <i>In vivo</i> kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection

    Yan Zhang, Diana L. Wallace, Catherine M. de Lara +8

    Мақола20073 иқтибос
    ABI

  10. CAR-NK cells: A promising cellular immunotherapy for cancer

    Guozhu Xie, Han Dong, Yong Liang +3

    Шарҳ мақола20203 иқтибос
    ABI

  11. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

    Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang +2

    Шарҳ мақола20213 иқтибос
    ABI

  12. Roles of IFN-γ in tumor progression and regression: a review

    Dragica Jorgovanović, Mengjia Song, Liping Wang +1

    Шарҳ мақола20203 иқтибос
    ABI

  13. Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

    Antonio Di Stasi, Siok‐Keen Tey, Gianpietro Dotti +17

    Мақола20112 иқтибос
    ABI

  14. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

    Congcong Zhang, Pranav Oberoi, Sarah Oelsner +4

    Мақола20172 иқтибос
    ABI

  15. Transforming Growth Factor-β Signaling in Immunity and Cancer

    Eduard Batlle, Joan Massagué

    Шарҳ мақола20192 иқтибос
    ABI

  16. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel +26

    Мақола20182 иқтибос
    ABI

  17. The inducible caspase-9 suicide gene system as a “safety switch†to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

    Tessa Gargett, Michael P. Brown

    Шарҳ мақола20142 иқтибос
    ABI

  18. Tracking the Evolution of Non–Small-Cell Lung Cancer

    Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicholas McGranahan +80

    Мақола20172 иқтибос
    ABI

  19. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson +15

    Мақола20162 иқтибос
    ABI

  20. Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways

    Yan Yang, Saiaditya Badeti, Hsiang-chi Tseng +5

    Мақола20202 иқтибос
    ABI

  21. Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules

    Stephanie Slania, Deepankar Das, Ala Lisok +7

    Мақола20212 иқтибос
    ABI

  22. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

    Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella +11

    Мақола20042 иқтибос
    ABI

  23. Human CD56bright NK Cells: An Update

    Tatiana Michel, Aurélie Poli, Angélica Cuapio +4

    Шарҳ мақола20162 иқтибос
    ABI

  24. Comprehensive genomic characterization of squamous cell lung cancers

    Gad Getz, Stephen E. Schumacher, Petar Stojanov +97

    Мақола20122 иқтибос
    ABI

  25. Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56<sup>bright</sup>CD16<sup>−</sup> cells and display an impaired capability to kill tumor cells

    Paolo Carrega, Barbara Morandi, Roberta Costa +7

    Мақола20082 иқтибос
    ABI